TSX symbol: SBS
CALGARY, June 4 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular diseases, today announced that Andrew Baum,
president & CEO of the company, will present a corporate update at the Needham
& Company, LLC Seventh Annual Biotechnology and Medical Technology Conference.
The presentation is scheduled on Wednesday, June 11 at 2:30 p.m., at the New
York Palace Hotel.
Interested parties may access a live webcast of the presentation by
visiting the company's website at www.sembiosys.com. Please connect at least
15 minutes prior to the presentation to ensure adequate time for any software
download that may be required to join the webcast. An audio archive of the
presentation will be available for approximately 30 days.
About SemBioSys Genetics Inc.
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing protein-based pharmaceuticals for metabolic and cardiovascular
diseases. The Company's lead pharmaceutical candidates, produced in the plant
host safflower, are recombinant human insulin to serve the rapidly expanding
global diabetes market and Apo AI, a next generation cardiovascular drug. In
addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco,
develops and supplies proprietary specialty ingredients to the personal care
industry. More information is available at www.sembiosys.com.
For further information:
For further information: SemBioSys Genetics Inc., Andrew Baum, President
and Chief Executive Officer, Phone: (403) 717-8767, E-mail:
email@example.com; The Trout Group, Ian Clements, Senior Vice President,
Phone: (415) 392-3385, E-mail: firstname.lastname@example.org